Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 3
1996 1
1997 2
1998 17
1999 49
2000 61
2001 165
2002 295
2003 356
2004 495
2005 599
2006 610
2007 725
2008 710
2009 684
2010 716
2011 672
2012 720
2013 727
2014 729
2015 672
2016 722
2017 684
2018 629
2019 289
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

9,989 results
Results by year
Filters applied: . Clear all
Page 1
PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT. BioDrugs 2018 - Review. PMID 30284704 Free PMC article.
The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from reference infliximab to GP1111 had no impact on safety, efficacy or immunogenicity. The role of reference infliximab in the management of autoimmune inflammatory conditions is well established and GP1111 provides an effective biosimilar alternative for patients requiring infliximab therapy....
The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from refe …
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD, et al. Lancet 2019 - Clinical Trial. PMID 30929895
Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab, or infliximab then CT-P13, with switching occurring at week 30. ...FINDINGS: Between Aug 20, 2014, and Feb 15, 2017, 308 patients were assessed for eligibility, and 220 patients were enrolled: 111 were randomly assigned to initiate CT-P13 (56 to the CT-P13-CT-P13 group and 55 to the CT-P13-infliximab group) and 109 to initiate infliximab (54 to the infliximab-infliximab group and 55 to the infliximab-CT-P13 group). ...
Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab
[Infliximab].
Goujon C, et al. Ann Dermatol Venereol 2019. PMID 31230775 French.
Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis.
Wu D, et al. Medicine (Baltimore) 2018. PMID 30313056 Free PMC article.
BACKGROUND: Infliximab and cyclosporine are two main therapies in treating acute severe ulcerative colitis (ASUC), our objective is to assess the effectiveness and safety of cyclosporine (CSA) versus infliximab (IFX) as rescue agents in patients with steroid-refractory ulcerative colitis (UC). METHODS: We will search three databases from inception to May 2018, and 19 studies are identified that infliximab and cyclosporine as a treatment in steroid-refractory UC patients. ...
BACKGROUND: Infliximab and cyclosporine are two main therapies in treating acute severe ulcerative colitis (ASUC), our objective is t …
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF, et al. World J Gastroenterol 2018 - Clinical Trial. PMID 30581277 Free PMC article.
One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who were switching from infliximab original to infliximab biosimilar (CT-P13). ...The overall efficacy for infliximab original per year of treatment was 71% vs 68.2% for infliximab biosimilar (P = 0.80). The loss of overall efficacy at 12 mo for infliximab original was 6.6% vs 14.5% for infliximab biosimilar (P = 0.806). ...
One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who w …
Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar.
Jentzer A, et al. Ther Drug Monit 2018. PMID 30439790
BACKGROUND: SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in the European Union for all IFX indications. Many decision algorithms based on the measurement of IFX trough levels and antibodies to infliximab are being increasingly used to optimize IFX treatment. ...
BACKGROUND: SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in th …
Minimum Infliximab Dosage for Keeping Serum Infliximab Levels Greater than 1 µg/mL among Patients with Rheumatoid Arthritis.
Kizaki K, et al. Biol Pharm Bull 2018. PMID 30504676 Free article.
Based on whether serum infliximab levels above/below 1 µg/mL and values led by the equation, infliximab dosage/infliximab interval/body weight (mg/weeks/kg), a receiver operating characteristic curve (ROC) was depicted with area under the ROC curve 0.750 and the cut-off point for the serum infliximab levels greater than 1 µg/mL was identified as infliximab dosage/infliximab interval/body weight ≧0.750 with the sensitivity 0.393 and the specificity 1.000. In conclusion, we identified that the minimum infliximab dosage to maintain serum infliximab levels greater than 1 µg/mL was infliximab dose/dosage interval/body weight (mg/weeks/kg)≥0.750....
Based on whether serum infliximab levels above/below 1 µg/mL and values led by the equation, infliximab dosage/infliximab
9,989 results
Jump to page
Feedback